PDE4 Long Form Activators for cAMP Signaling Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for structurally distinct small molecule activators of PDE4 long forms for therapeutic use, as existing activators have not been reported in clinical development, and current technologies lack effective methods for reducing excessive intracellular cAMP signaling associated with various disorders.
Innovation Solution
Development of compounds of Formula I, which are small molecules that selectively activate PDE4 long form enzymes, thereby reducing cAMP levels and providing therapeutic benefits for disorders mediated by excessive cAMP signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule activators of PDE4 long forms are developed for therapeutic use, then excessive intracellular cAMP signaling can be reduced, but no such activators have been reported in clinical development
Solution Approach 1:
The patent segments the PDE4 enzyme family by developing activators that specifically target long forms (PDE4A, PDE4B, PDE4C, PDE4D) while excluding short forms. This is achieved through structural design of compounds that exploit the unique UCR1 domain present only in long forms, enabling selective therapeutic action on cAMP degradation pathways in diseases where this selectivity is critical.
Solution Approach 2:
The patent employs parameter changes by modifying molecular structure parameters of PDE4 activators. The compounds feature specific structural elements (aromatic rings, heterocyclic systems, substituent patterns) that tune binding affinity and selectivity for PDE4 long forms. This systematic variation of molecular parameters has generated a series of activators with optimized therapeutic profiles for clinical development.
2Object-affected harmful factors
If PDE4 long forms are selectively activated to reduce cAMP levels, then disorders mediated by excessive cAMP signaling can be treated, but existing activators lack structural distinction and clinical development
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional regions that interact with distinct pockets in the PDE4 long form active site. The molecular structures incorporate localized aromatic and heterocyclic systems with specific substituent patterns that create unique binding geometries, enabling selective activation of long forms while providing a diverse series of structurally distinct activators for therapeutic development.
3Quantity of substance
If compounds of Formula I are developed as PDE4 activators, then intracellular cAMP levels can be reduced for therapeutic benefit, but no structurally distinct small molecule activators have been reported
Solution Approach 1:
The patent achieves universality by creating a platform of compounds (Formula I and Formula II) that share core structural features enabling PDE4 long form activation, while allowing diverse substituent variations. This modular design provides both structural distinctness across the series and ease of manufacturing through common synthetic pathways, generating multiple activators with similar therapeutic profiles for clinical development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively activate PDE4 long forms, reducing intracellular cAMP levels, offering potential therapeutic benefits for a range of disorders including hyperthyroidism, polycystic kidney disease, and other conditions characterized by excessive cAMP activity.
Implementation Method 1
PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5'-AMP
Implementation Method 2
PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5'-AMP
Data Source
AI summary
The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).